Opus Point Partners Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Opus Point Partners Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.4M	Buy	8,279 +86	+1%	+$15.2K	2.54%	8
2019 Q2	$1.5M	Buy	8,193 +119	+1%	+$20.8K	2.22%	6
2019 Q1	$1.49M	Sell	8,074 -590	-7%	-$109K	2.01%	8
2018 Q4	$1.44M	Sell	8,664 -63	-0.7%	-$10.9K	3.16%	7
2018 Q3	$1.68M	Sell	8,727 -604	-6%	-$108K	4.02%	7
2018 Q2	$1.59M	Buy	9,331 +107	+1%	+$16.6K	3.44%	6
2018 Q1	$1.5M	Sell	9,224 -7,415	-45%	-$1.21M	2.95%	9
2017 Q4	$2.49M	Sell	16,639 -1,635	-9%	-$242K	2.16%	14
2017 Q3	$2.78M	Sell	18,274 -720	-4%	-$108K	2.49%	11
2017 Q2	$2.45M	Sell	18,994 -15,012	-44%	-$1.81M	2.24%	15
2017 Q1	$3.72M	Buy	34,006 +649	+2%	+$57.1K	2.76%	14
2016 Q4	$2.46M	Buy	33,357 +1,216	+4%	+$98.9K	1.96%	23
2016 Q3	$2.8M	Buy	32,141 +1,893	+6%	+$179K	1.57%	25
2016 Q2	$2.6M	Sell	30,248 -10,889	-26%	-$941K	2.51%	15
2016 Q1	$3.27M	Sell	41,137 -525	-1%	-$47.5K	2.53%	17
2015 Q4	$5.24M	Buy	41,662 +786	+2%	+$94.9K	3.46%	11
2015 Q3	$4.26M	Buy	40,876 +5,600	+16%	+$719K	2.35%	18
2015 Q2	$4.36M	Buy	35,276 +2,471	+8%	+$311K	3.45%	13
2015 Q1	$3.87M	Buy	32,805 +3,709	+13%	+$444K	3.24%	12
2014 Q4	$3.46M	Buy	+29,096	New	+$3.28M	3.42%	8

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Opus Point Partners Management's VRTX Position: Q3 2019 in Review

Opus Point Partners Management increased its Vertex Pharmaceuticals (VRTX) stake by 1% in Q3 2019, buying an estimated $15.2K and bringing the position to 8,279 shares worth $1.4M. The position accounts for 2.54% of the portfolio, ranked #8.

Opus Point Partners Management first reported a position in VRTX in Q4 2014 and has held it in 20 quarters since. The position peaked at $5.24M in Q4 2015. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Opus Point Partners Management held 8,279 shares of Vertex Pharmaceuticals worth $1.4M as of Q3 2019.
Opus Point Partners Management bought 86 Vertex Pharmaceuticals shares in Q3 2019, an estimated $15.2K.
Vertex Pharmaceuticals made up 2.54% of Opus Point Partners Management's portfolio in Q3 2019, its #8 holding.
Opus Point Partners Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
Opus Point Partners Management's Vertex Pharmaceuticals position peaked at $5.24M in Q4 2015.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.